Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Qnity Electronics Inc. Common Stock (Q) vs TG Therapeutics Inc (TGTX) Price & Performance

Qnity Electronics Inc. Common StockTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Qnity Electronics Inc. Common Stock vs TG Therapeutics Inc — how do they compare? Qnity Electronics Inc. Common Stock trades at $126.54 (market cap $26.50B), while TG Therapeutics Inc trades at $54.83 (market cap $8.16B). The key difference: Qnity Electronics Inc. Common Stock is far larger — about 3.2× TG Therapeutics Inc's market cap, and Qnity Electronics Inc. Common Stock pays a 0.25% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Qnity Electronics Inc. Common Stock for 1 Days and TG Therapeutics Inc for 16 Days on average.

QTGTX
Market Cap
$26.50B$8.16B
Volume
1,501,0841,735,121
Sector
TechnologyHealth
52-Week High
$175.64$59.06
52-Week Low
$73.54$26.94
Typical Hold Time
1 Days16 Days
Enterprise Value
$29.56B$8.37B
Dividend Yield
0.25%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Qnity Electronics Inc. Common Stock

No Aura AI signal available yet.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.

The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

Q

No sentiment data available yet.

TGTX
0% Buy100% Sell
Avg holding period · 16 Days

About Qnity Electronics Inc. Common Stock

Qnity Electronics provides materials and solutions for semiconductor manufacturing and electronic systems. Its portfolio supports chip fabrication, advanced packaging, interconnects, and thermal management.

Read more on Q →

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX →